Market Place
Sourcing Support
Medexus Pharma Announces C$10 Million Bought-Deal Public Offering of Units
05 Sep 2023 //
GLOBENEWSWIRE
Medexus to Participate in the 2023 Bloom Burton & Co. Healthcare Conference
18 Apr 2023 //
GLOBENEWSWIRE
Medexus Expects Record Revenue for Fiscal Year 2023 and Provides Business Update
11 Apr 2023 //
GLOBENEWSWIRE
Medexus Announces New License Deal for Topical Terbinafine
22 Mar 2023 //
GLOBENEWSWIRE
Medexus to Participate in 35th Annual Roth Conference
06 Mar 2023 //
GLOBENEWSWIRE
Medexus Announces Record Quarter with Fiscal Q3 2023 Revenue of US$28.7M
08 Feb 2023 //
GLOBENEWSWIRE
Medexus Welcomes Two New Board Members
06 Feb 2023 //
GLOBENEWSWIRE
Medexus Secures Public Reimbursement for Cuvposa® in Quebec
01 Feb 2023 //
GLOBENEWSWIRE
Medexus Schedules Third Fiscal Quarter 2023 Conference Call
31 Jan 2023 //
GLOBENEWSWIRE
Medexus Expects Record Revenue for Fiscal Q3 2023 and Provides Business Update
12 Jan 2023 //
GLOBENEWSWIRE
Medexus Announces Strongest Quarter in Company History with Fiscal Q2 2023
09 Nov 2022 //
GLOBENEWSWIRE
Medexus and MidCap Agree to Increase in MidCap’s Revolving Loan
29 Sep 2022 //
GLOBENEWSWIRE
Medexus Provides Update on Treosulfan NDA Resubmission Provides Business Update
19 Sep 2022 //
GLOBENEWSWIRE
Medexus Announces Record Fiscal Q1 2023 Revenue of US$23.0 Million
08 Aug 2022 //
GLOBENEWSWIRE
Medexus Schedules First Quarter 2023 Conference Call
02 Aug 2022 //
GLOBENEWSWIRE
Medexus Pharma Resubmits Treosulfan NDA To FDA
26 Jul 2022 //
NASDAQ
Medexus Generates Revenue of US$76.7M in FY 2022 and US$20.3M in Fiscal Q4
22 Jun 2022 //
GLOBENEWSWIRE
Medexus Schedules Fourth Quarter and Fiscal Year 2022 Conference Call
14 Jun 2022 //
GLOBENEWSWIRE
Medexus Pharmaceuticals Provides Update on Resubmission of Treosulfan NDA
24 May 2022 //
GLOBENEWSWIRE
Medexus Pharmaceuticals Announces Resubmission of Treosulfan NDA
22 Apr 2022 //
GLOBENEWSWIRE
Medexus Pharmaceuticals Announces Resubmission of Treosulfan NDA
21 Apr 2022 //
MEDEXUS
Medexus to Present at the Bloom Burton & Co. Healthcare Investor Conference
19 Apr 2022 //
GLOBENEWSWIRE
Medexus to Participate in the 34th Annual Roth Conference
09 Mar 2022 //
GLOBENEWSWIRE
Medexus Pharmaceuticals Announces Deal for Gleolan in the United States
01 Mar 2022 //
GLOBENEWSWIRE
Medexus Announces Normal Course Issuer Bid, or NCIB, for Convertible Debentures
14 Feb 2022 //
GLOBENEWSWIRE
Medexus Pharma Generated $21.3M in Fiscal 2022 Third Quarter Revenues
09 Feb 2022 //
GLOBENEWSWIRE
Medexus to Present at The MicroCap Rodeo’s 2nd Annual Winter Wonderland
01 Feb 2022 //
GLOBENEWSWIRE
Medexus Pharmaceuticals Announces Clear Path to FDA Decision Following medac’s
02 Dec 2021 //
GLOBENEWSWIRE
Medexus Pharmaceuticals Reports Financial and Operational Results for the Three
10 Nov 2021 //
GLOBENEWSWIRE
Medexus Holds Annual and Special Meeting of Shareholders
16 Sep 2021 //
GLOBENEWSWIRE
Medexus Pharmaceuticals Reports Financial and Operational Results
16 Aug 2021 //
GLOBENEWSWIRE
Medexus Schedules First Quarter Fiscal 2022 Conference Call
10 Aug 2021 //
GLOBENEWSWIRE
Medexus Schedules First Quarter Fiscal 2022 Conference Call
10 Aug 2021 //
GLOBENEWSWIRE
Complete Response Letter Received from FDA for Treosulfan
03 Aug 2021 //
FINANCIAL POST
Medexus and medac GmbH enter into Licensing Agreement for Treosulfan, in Canada
12 Jul 2021 //
GLOBENEWSWIRE
Medexus Receives Notice of Compliance to Commercialize Treosulfan in Canada
28 Jun 2021 //
GLOBENEWSWIRE
Medexus Announces Graduation to the Toronto Stock Exchange
15 Jun 2021 //
GLOBENEWSWIRE
Medexus Announces Availability of Triamcinolone Hexacetonide in the US
09 Jun 2021 //
GLOBENEWSWIRE
Medexus Announces Amendments to its Credit Agreements
27 May 2021 //
FINANCIALPOST
Medexus Announces Expanded Availability of Gleolan® in Canada
25 Feb 2021 //
GLOBENEWSWIRE
Medexus and medac GmbH enter into a License Agreement for First-in-Class Agent
02 Feb 2021 //
GLOBENEWSWIRE
Medexus (MDP.V) expands specialty pharmaceuticals portfolio
22 Dec 2020 //
PRNEWSWIRE
Medexus Enters into Exclusive License to Register and Commercialize TH
18 Dec 2020 //
GLOBENEWSWIRE
Medexus Enters into Exclusive License to Register and Commercialize (TH)
18 Dec 2020 //
GLOBENEWSWIRE
Medexus Reaches 50% Enrollment in IXINITY® Ph 4 Clinical Trial Targeting Label
16 Nov 2020 //
GLOBENEWSWIRE
Medexus Reports Health Canada Approval of Gleolan® (5-ALA)
10 Sep 2020 //
BIOSPACE
Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved
24 Aug 2020 //
GLOBENEWSWIRE
Medexus Pharmaceuticals Reports Record Revenue of $27.5 Million and $5.0 M
11 Aug 2020 //
GLOBENEWSWIRE
Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved
09 Jul 2020 //
GLOBENEWSWIRE
Medexus Provides an Update on the IXINITY® Acquisition and its Overall Business
22 May 2020 //
GLOBENEWSWIRE
Medexus expands US product portfolio by acquiring hematology asset IXINITY
28 Feb 2020 //
PROACTIVEINVESTORS
